Retatrutide (LY3437943) is a single-molecule triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has shown superior weight reduction outcomes compared to dual GIP/GLP-1 agonists in published Phase 2 data. The glucagon receptor component adds thermogenic effects not seen with GLP-1 alone. NewChem supplies research-grade Retatrutide at ≥99% HPLC purity for preclinical research applications.
Add 2 mL bacteriostatic water for 5,000 mcg/mL. Store reconstituted peptide away from light.
Use our peptide reconstitution calculator →
Store lyophilised at −20 °C. Reconstituted: 4 °C, use within 21 days.
Every NewChem batch of Retatrutide is independently tested prior to dispatch. Your COA documents HPLC purity (≥99%), identity confirmation via mass spectrometry, endotoxin screening, and a unique batch ID for full traceability. Sample COAs are available on request before purchase.
For a detailed step-by-step reconstitution guide for Retatrutide, including BAC water measurements, syringe unit conversions, and storage protocols, see our dedicated guide:
